Valion Bio, Inc. Common Stock (VBIO) Competitors

$0.85 0.00 (0.00%)

As of 05/22/2026 04:00 PM Eastern

VBIO vs. QNRX, ALUR, LFWD, VVOS, and SINT

Should you buy Valion Bio, Inc. Common Stock stock or one of its competitors? MarketBeat compares Valion Bio, Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Valion Bio, Inc. Common Stock include Quoin Pharmaceuticals (QNRX), Allurion Technologies (ALUR), Lifeward (LFWD), Vivos Therapeutics (VVOS), and Sintx Technologies (SINT). These companies are all part of the "medical equipment" industry.

How does Valion Bio, Inc. Common Stock compare to Quoin Pharmaceuticals?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

In the previous week, Quoin Pharmaceuticals and Quoin Pharmaceuticals both had 1 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 0.00 equaled Valion Bio, Inc. Common Stock'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 13.5% of Quoin Pharmaceuticals shares are owned by company insiders. Comparatively, 14.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valion Bio, Inc. Common Stock has higher revenue and earnings than Quoin Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
Valion Bio, Inc. Common Stock	$780K	3.50	-$8.88M	-$6.68	N/A

Quoin Pharmaceuticals has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

Summary

Valion Bio, Inc. Common Stock beats Quoin Pharmaceuticals on 8 of the 9 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Allurion Technologies?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Allurion Technologies has higher revenue and earnings than Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	3.50	-$8.88M	-$6.68	N/A
Allurion Technologies	$17.21M	0.72	-$7.20M	-$10.56	N/A

Allurion Technologies has a consensus price target of $3.00, indicating a potential upside of 261.71%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Allurion Technologies is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
Allurion Technologies	-199.96%	N/A	-77.13%

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 1 mentions for Valion Bio, Inc. Common Stock and 0 mentions for Allurion Technologies. Valion Bio, Inc. Common Stock's average media sentiment score of 0.00 equaled Allurion Technologies'average media sentiment score.

Company	Overall Sentiment
Valion Bio, Inc. Common Stock	Neutral
Allurion Technologies	Neutral

4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 14.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Comparatively, 8.1% of Allurion Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valion Bio, Inc. Common Stock has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market.

Summary

Allurion Technologies beats Valion Bio, Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Lifeward?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Lifeward has a consensus target price of $10.00, indicating a potential upside of 41.84%. Given Lifeward's stronger consensus rating and higher probable upside, analysts clearly believe Lifeward is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lifeward	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	3.50	-$8.88M	-$6.68	N/A
Lifeward	$22.03M	0.49	-$19.91M	-$19.66	N/A

In the previous week, Lifeward had 4 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 5 mentions for Lifeward and 1 mentions for Valion Bio, Inc. Common Stock. Lifeward's average media sentiment score of 0.16 beat Valion Bio, Inc. Common Stock's score of 0.00 indicating that Lifeward is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifeward	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Lifeward's net margin of -123.66%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
Lifeward	-123.66%	-243.14%	-97.39%

Valion Bio, Inc. Common Stock has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 14.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Comparatively, 1.5% of Lifeward shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Valion Bio, Inc. Common Stock beats Lifeward on 9 of the 16 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Vivos Therapeutics?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Vivos Therapeutics has a consensus price target of $2.75, indicating a potential upside of 350.82%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	3.50	-$8.88M	-$6.68	N/A
Vivos Therapeutics	$17.44M	0.49	-$21.17M	-$2.14	N/A

Valion Bio, Inc. Common Stock has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.25, indicating that its share price is 525% more volatile than the broader market.

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 14.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Vivos Therapeutics had 6 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 7 mentions for Vivos Therapeutics and 1 mentions for Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock's average media sentiment score of 0.00 beat Vivos Therapeutics' score of -0.17 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vivos Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -127.70%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

Summary

Valion Bio, Inc. Common Stock and Vivos Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Sintx Technologies?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Sintx Technologies' net margin of -1,058.60%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
Sintx Technologies	-1,058.60%	-366.49%	-115.04%

Valion Bio, Inc. Common Stock has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market. Comparatively, Sintx Technologies has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Sintx Technologies. Sintx Technologies is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	3.50	-$8.88M	-$6.68	N/A
Sintx Technologies	$1.02M	10.12	-$10.36M	-$5.07	N/A

Sintx Technologies has a consensus price target of $11.00, suggesting a potential upside of 360.25%. Given Sintx Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Sintx Technologies is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Sintx Technologies had 9 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 10 mentions for Sintx Technologies and 1 mentions for Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock's average media sentiment score of 0.00 equaled Sintx Technologies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sintx Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 14.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Comparatively, 4.1% of Sintx Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Sintx Technologies beats Valion Bio, Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

Get Valion Bio, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VBIO vs. The Competition

Export

Metric	Valion Bio, Inc. Common Stock	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.73M	$1.44B	$6.46B	$12.34B
Dividend Yield	N/A	N/A	2.76%	5.28%
P/E Ratio	-0.13	64.56	21.22	25.66
Price / Sales	3.50	6.30	562.28	86.31
Price / Cash	N/A	22.72	43.49	56.67
Price / Book	0.25	7.38	10.31	7.14
Net Income	-$8.88M	-$54.76M	$3.57B	$335.98M
7 Day Performance	5.00%	3.02%	6.43%	4.15%
1 Month Performance	-35.91%	6.69%	3.57%	2.54%
1 Year Performance	-79.26%	1.47%	34.07%	35.06%

Valion Bio, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VBIO Valion Bio, Inc. Common Stock	0.7775 of 5 stars	$0.85 flat	N/A	-79.3%	$2.73M	$780K	N/A	10	Gap Up
QNRX Quoin Pharmaceuticals	0.112 of 5 stars	$5.91 -2.6%	N/A	-46.0%	$10.66M	N/A	N/A	4	Positive News
ALUR Allurion Technologies	N/A	$0.70 -12.5%	$3.00 +328.6%	-70.1%	$10.50M	$17.21M	N/A	501	Gap Down
LFWD Lifeward	1.9284 of 5 stars	$6.63 +2.2%	$10.00 +50.8%	-53.4%	$10.14M	$22.03M	N/A	60
VVOS Vivos Therapeutics	2.8996 of 5 stars	$0.72 -1.4%	$2.58 +260.6%	-73.2%	$9.82M	$17.44M	N/A	160	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VBIO) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. QNRX, ALUR, LFWD, VVOS, and SINT

How does Valion Bio, Inc. Common Stock compare to Quoin Pharmaceuticals?

Summary

How does Valion Bio, Inc. Common Stock compare to Allurion Technologies?

Summary

How does Valion Bio, Inc. Common Stock compare to Lifeward?

Summary

How does Valion Bio, Inc. Common Stock compare to Vivos Therapeutics?

Summary

How does Valion Bio, Inc. Common Stock compare to Sintx Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. QNRX, ALUR, LFWD, VVOS, and SINT

How does Valion Bio, Inc. Common Stock compare to Quoin Pharmaceuticals?

Is QNRX or VBIO more profitable?

Does the media favor QNRX or VBIO?

Do analysts recommend QNRX or VBIO?

Do insiders and institutionals have more ownership in QNRX or VBIO?

Which has higher valuation & earnings, QNRX or VBIO?

Which has more risk & volatility, QNRX or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to Allurion Technologies?

Which has higher earnings and valuation, VBIO or ALUR?

Do analysts recommend VBIO or ALUR?

Is VBIO or ALUR more profitable?

Does the media prefer VBIO or ALUR?

Do insiders & institutionals have more ownership in VBIO or ALUR?

Which has more risk and volatility, VBIO or ALUR?

Summary

How does Valion Bio, Inc. Common Stock compare to Lifeward?

Do analysts rate VBIO or LFWD?

Which has stronger valuation and earnings, VBIO or LFWD?

Does the media prefer VBIO or LFWD?

Is VBIO or LFWD more profitable?

Which has more risk & volatility, VBIO or LFWD?

Do insiders & institutionals believe in VBIO or LFWD?

Summary

How does Valion Bio, Inc. Common Stock compare to Vivos Therapeutics?

Do analysts rate VBIO or VVOS?

Which has preferable valuation & earnings, VBIO or VVOS?

Which has more volatility & risk, VBIO or VVOS?

Do insiders and institutionals have more ownership in VBIO or VVOS?

Does the media refer more to VBIO or VVOS?

Is VBIO or VVOS more profitable?

Summary

How does Valion Bio, Inc. Common Stock compare to Sintx Technologies?

Is VBIO or SINT more profitable?

Which has more risk and volatility, VBIO or SINT?

Which has higher valuation & earnings, VBIO or SINT?

Do analysts prefer VBIO or SINT?

Does the media prefer VBIO or SINT?

Do institutionals and insiders hold more shares of VBIO or SINT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools